Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment
Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment
复制标题
DOI：
10.1111/j.1464-410x.2010.09716.x
复制
发表时间：
2011-07-01
影响因子：
4.5
通讯作者：
Chancellor, Michael B.
中科院分区：
文献类型：
--
作者：
Watanabe, Toyohiko;Inoue, Miayabi;Chancellor, Michael B.
目的探讨前列腺液（EPS）中神经生长因子（NGF）水平与慢性前列腺炎（CP）和慢性盆腔疼痛综合征（CPPS）症状严重程度的关系。并根据美国国立卫生研究院慢性前列腺炎症状指数进行评分收集并冷冻来自20名CP/CPPS患者和4名无症状对照患者的表达的前列腺分泌物样品，用酶联免疫吸附法测定EPS和NGF水平。在基线和治疗后8周的CPSI问卷调查和总NIH-CPSI评分从基线值降低至少25%的患者被分类为治疗应答者。CPPS和无症状对照患者分别为7409（+/-3788）pg/mL和4174（+/-1349）pg/mL。CP/CPPS患者治疗前后EPS中NGF水平与疼痛程度呈正相关（P = 0.014，r = 0.541），治疗前后EPS中NGF水平无显著性差异。然而，成功的治疗显着降低了反应者的NGF水平（P = 0.001）。结论神经生长因子可能有助于CP/CPPS的病理生理变化的神经生长因子水平在EPS发生成比例的疼痛严重程度。因此，这些结果表明，NGF可以作为一种新的生物标志物来评估CP/CPPS的症状和治疗效果。
OBJECTIVETo explore whether levels of nerve growth factor (NGF) in expressed prostatic secretions (EPS) are correlated with symptom severity in chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS).PATIENTS AND METHODSAll patients with CP/CPPS underwent a complete history and physical examination, and were scored according to the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).Expressed prostatic secretion samples from 20 patients with CP/CPPS and from four asymptomatic control patients were collected and frozen, and NGF levels in EPS were measured by enzyme-linked immunosorbent assay.Patients were asked to complete NIH-CPSI questionnaires at baseline and 8 weeks after treatment and patients with at least a 25% decrease in total NIH-CPSI score from the baseline values were classified as responders to treatment.RESULTSThe mean (+/-SD) NGF levels in EPS of patients with CP/CPPS and asymptomatic control patients were 7409 (+/-3788) pg/mL and 4174 (+/-1349) pg/mL, respectively. The NGF level in patients with CP/CPPS correlated directly with pain severity (P = 0.014, r = 0.541).There were no significant differences between NGF levels in EPS before and after treatment. However, successful treatment significantly decreased NGF levels in responders (P = 0.001).CONCLUSIONNerve growth factor might contribute to the pathophysiology of CP/CPPS as changes in NGF level in EPS occurred in proportion to pain severity. Therefore, these results suggest that NGF could be used as a new biomarker to evaluate the symptoms of CP/CPPS and the effects of treatment.